-
PDI Inhibition Enhances Panobinostat Efficacy in Myeloma Mod
2026-04-24
This study introduces a novel approach for relapsed/refractory multiple myeloma by combining the PDI inhibitor LTI6426 with the HDAC inhibitor panobinostat. The combination markedly boosts anti-myeloma efficacy in preclinical models, suggesting a safe, lower-dose strategy that could mitigate toxicity and identify new biomarkers of therapeutic response.
-
Advancing In Vitro Drug Response Evaluation in Cancer Resear
2026-04-24
Schwartz's dissertation critically re-examines how in vitro assays measure anticancer drug responses, distinguishing between proliferative arrest and cell death. By clarifying these metrics, the work supports more precise evaluation of therapies like VEGFR inhibitors in preclinical oncology.
-
Scenario-Based Solutions with Recombinant Human Growth Hormo
2026-04-23
This article addresses common laboratory challenges in cell proliferation and viability assays, focusing on how Recombinant Human Growth Hormone (GH) (SKU P1223) provides reproducible, validated solutions for biomedical researchers. Through scenario-driven Q&A and data-backed recommendations, bench scientists gain actionable insights into optimizing workflows with this high-purity, biologically active somatotropin reagent.
-
Pseudo-UTP in mRNA Synthesis: Enhancing RNA Stability and Tr
2026-04-23
Pseudo-modified uridine triphosphate (Pseudo-UTP) unlocks robust RNA stability and high translation efficiency—key for mRNA vaccines and gene therapy. This article delivers actionable workflows, troubleshooting tips, and comparative insights for optimizing your next mRNA synthesis using Pseudo-UTP from APExBIO.
-
SB 202190: Precision p38 MAPK Inhibition in Organoid Oncolog
2026-04-22
Explore the scientific depth of SB 202190 as a selective p38 MAP kinase inhibitor in advanced cancer organoid research. Discover how its unique ATP-competitive mechanism enables breakthrough applications in inflammation and drug resistance modeling.
-
Amitriptyline HCl (B2231): Practical Guidance for Lab Resear
2026-04-22
Amitriptyline HCl (SKU B2231) provides a high-purity, well-characterized tool for studying neurotransmitter receptor modulation, especially in neuropharmacology and mood disorder research workflows. It is suitable for in vitro and in vivo assays requiring potent, multi-receptor inhibition but should not be used where long-term solution stability is necessary. Researchers can rely on its defined solubility and storage parameters to ensure reproducible outcomes.
-
Amitriptyline HCl: Protocols and QC for Neuropharmacology Re
2026-04-21
Amitriptyline HCl provides a reliable tool for investigating neurotransmitter receptor modulation and related neuropharmacology workflows. This compound is best suited for CNS-focused assays requiring high solubility and purity; it is not validated for long-term solution storage or non-neuroscience applications.
-
Latrunculin A: Mechanistic Precision for Translational Cytos
2026-04-21
This thought-leadership article explores how Latrunculin A, a potent reversible inhibitor of actin assembly, is redefining actin cytoskeleton research and translational strategies. By synthesizing new proteomic findings, mechanistic insights, and workflow guidance, it illuminates best practices for dissecting cytoskeletal regulation in contexts ranging from tumor biology to host–virus interactions. The article also positions APExBIO’s Latrunculin A as a gold-standard reagent, contrasting its value against prevailing products and methodologies.
-
Rhodamine B (SKU A4705): Reliable Solutions in Cell Assays
2026-04-20
Discover how Rhodamine B (SKU A4705) addresses challenges in cell viability, proliferation, and cytotoxicity assays with data-backed, scenario-driven guidance. This article provides laboratory researchers with practical insights into optimizing fluorescent labeling, ensuring reproducible results, and selecting reliable suppliers for robust experimental outcomes.
-
Amitriptyline HCl (B2231): Technical Guidance for Research U
2026-04-20
Amitriptyline HCl is a validated tricyclic compound for dissecting neurotransmitter receptor modulation in neuropharmacology and mood disorder research. It is best suited for controlled in vitro and cell-based assays where receptor-specific inhibition is required, but should not be extrapolated to untested systems or long-term solution storage due to sensitivity constraints.
-
Staurosporine: Broad-Spectrum Kinase Inhibitor for Cancer As
2026-04-19
Staurosporine stands as the gold-standard broad-spectrum serine/threonine protein kinase inhibitor, enabling robust and reproducible induction of apoptosis in cancer cell lines. This guide unpacks advanced workflows, quantitative protocol enhancements, and troubleshooting strategies, empowering researchers to maximize Staurosporine’s impact in cell signaling and anti-angiogenesis studies.
-
Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV
2026-04-18
Sidach and Mintz's study redefines the pharmacological landscape of neuronal calcium channels, revealing that v-agatoxin-IVA, previously considered a selective P-type Ca channel blocker, also exhibits low-affinity inhibition of N-type channels at higher concentrations. These findings challenge conventional channel classification and have direct implications for experimental strategies involving calcium channel blockers in neurophysiological and neurodegenerative research.
-
METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC
2026-04-17
Wang et al. (2024) identify a novel METTL16-SENP3-LTF signaling axis that confers ferroptosis resistance and promotes tumorigenesis in hepatocellular carcinoma. This mechanistic insight advances understanding of iron metabolism and cell death regulation, highlighting new molecular targets for sensitizing HCC to ferroptosis-based therapies.
-
Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2
2026-04-16
This study identifies merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro), a key enzyme in viral replication. The findings highlight the specificity of merbromin’s inhibitory action and provide a molecular scaffold for future antiviral drug design.
-
T-5224 (C-Fos/AP-1 Inhibitor): Protocols and Innovations for
2026-04-15
T-5224, a selective C-Fos/AP-1 inhibitor supplied by APExBIO, enables precise modulation of inflammatory and osteoclastogenic pathways in both cell-based and in vivo models. This article delivers actionable protocols, troubleshooting guidance, and novel translational insights—grounded in the latest neuroinflammatory research—to empower arthritis and pain investigators.